NCT05416268 is a NA clinical trial of Electroretinography in Retinal Disease, sponsored by Diopsys, Inc..

Who is sponsoring NCT05416268?

NCT05416268 is sponsored by Diopsys, Inc..

What drugs are being tested in NCT05416268?

Interventions in NCT05416268: Electroretinography.

What condition does NCT05416268 study?

NCT05416268 studies Retinal Disease.

Is NCT05416268 still recruiting?

NCT05416268 is currently completed. Last updated 14 June 2022.

Last reviewed 2022-06-14 · How we verify

NCT05416268

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Compare the Diopsys NOVA and LKC RETeval Devices

Completed NA Last updated 14 June 2022

What this trial tests

NA trial testing Electroretinography in Retinal Disease in 20 participants. Completed in 6 May 2022.

Timeline

4 May 2022

Primary endpoint
6 May 2022

6 May 2022

Quick facts

Lead sponsor	Diopsys, Inc.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	crossover
Masking	none
Primary purpose	diagnostic
Enrollment	20
Start date	4 May 2022
Primary completion	6 May 2022
Estimated completion	6 May 2022
Sites	1 location across United States

Drugs / interventions tested

Electroretinography

Conditions studied

Retinal Disease — all drugs for Retinal Disease →

Sponsor

Diopsys, Inc.

Who can join

22 and older, any sex, with Retinal Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To compare the Diopsys NOVA and LKC RETeval Devices using the Diopsys Lid Electrodes and LKC RETeval Self-Adhering Electrode Arrays.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Retinal Disease

Currently open trials in the same condition.

NCT07149740 — Data Gathering for A10900 · recruiting
NCT06852963 — A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Parti · Phase 1, PHASE2 · recruiting
NCT05699096 — Perfluorooctyl Bromide Which Empowers the Liquid to Flat the Detached Retina and Displace the Underneath Fluids Anterior · recruiting
NCT06289452 — Safety and Efficacy Study of IVB102 Injection in Subjects With X-linked Retinoschisis · EARLY_PHASE1 · active not recruiting
NCT06520410 — Safety and Efficacy of 18 mm Short Vitrectomy Probe for Pediatric Vitreoretinal Surgeries · Phase 4 · recruiting

Other Diopsys, Inc. trials

Trials by the same sponsor.

NCT02594280 — Benchmarking Management of Glaucoma Using the Diopsys VEP/PERG Protocols. · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05416268 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Diopsys, Inc.
Last refreshed: 14 June 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05416268.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing